Taken together, targeting of the TLR4/NLRP3/NF-κB and GSK3β-Nrf2/HO-1 signaling axes may contribute to the inhibition of oxidative stress, neuroinflammation, and apoptosis, hence promoting neuroprotection and exerting potential therapeutic effects against PD. This evidence concerns the gene NLRP3 and Parkinson disease.